Mpox in Europe: why WHO has reassessed risk for MSM — and what applies in Switzerland
by Queer Switzerland editorialPublished August 14, 20263 min read
What has changed in Europe WHO/Europe now describes clade Ib mpox transmission beyond travel-linked households. Four countries in the Region have reported cases without travel links, and several cases involve men who have sex with men (MSM). WHO therefore currently assesses mpox risk outside historically endemic areas as moderate for MSM and low for the general population. This is a risk assessment for a group with particular exposures, not a claim about who can become infected: anyone can catch mpox through close contact with an infectious person.
What this means in Switzerland Switzerland's Federal Office of Public Health (FOPH) still describes the national situation as stable. Only a few sporadic clade II cases have been reported since autumn 2022. Switzerland detected its first clade Ib case in early April in a traveller returning from Africa; according to the FOPH, there was no risk to the person's contacts or the broader public. The European change is therefore a reason to keep an eye on official guidance, not to issue sweeping warnings about Switzerland's queer community.
The practical view before travel, a party or a festival The FOPH advises mpox vaccination counselling particularly for MSM and trans people who frequently change male sexual partners. Vaccination may also be recommended after a relevant contact, ideally within four and up to 14 days; the individual decision belongs with a specialist health professional. Switzerland's compulsory health insurance covers mpox vaccination under the applicable conditions. Anyone who may have been exposed or suspects mpox should avoid close skin contact for the moment and seek medical advice promptly.
Do not turn a virus into an identity label Mpox does not belong to a sexual orientation. Contact and exposure matter, not identity. Good public-health communication names the groups in which more transmission is currently being observed without stigmatising them, and connects that information with accessible counselling, vaccination and clinical assessment. This article summarises public-health information and is not a diagnosis or individual medical advice.
Source: WHO/Europe / Swiss Federal Office of Public Health (FOPH)
